None listed
Conditions
Interventions
Dietary Supplement : 1. Test group
• Main ingredient name: Brainon (Ginseng Extract)
• Appearance and dosage form: brown, oblong coated tablet
• Content: 700 mg/tablet
• Storage Method: Store in a coo
Sponsors
NUON
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Men and women over 55 years old and under 85 years old 2) Those who can read Korean 3) A person whose memory score on CERAD-K decreased by more than 1.0 SD compared to the same education level and age group 4) A person who agreed to participate in this human application test before the human application test started and filled out the informed consent form
Exclusion criteria
Exclusion criteria: 1) Severe functional system, feeding system, coordinator/hepatic and biliary system, nerve and urinary system, nervous system, musculoskeletal system, joint monitor, and arthroma, etc. Current thermostat (however, considering the condition of the subject for human application test, the tester measurement of and can participate in the test accordingly.) 2) Current state (DSM-5 standards), persons with mental conditions such as schizophrenia, withdrawal, and drug dependence 3) Within (DSM-5 standards), those who have a manuscript loaded with understanding functions such as Parkinson's 4) Those who have had a head attack accompanied by loss of consciousness within 6 months of visit 1, and a cardio-cerebrovascular intestine (angina pectoris, myocardial infarction, transient ischemic attack, sedation, etc.) 5) Those who have experienced outside estrogen replacement therapy (excluding topical application) within 2 months of visit 1 6) Interventions affecting visual field function within 4 weeks of visit 1 (antipsychotics, degenerative spinal agents, brain function improving agents, tricyclic antidepressants) 7) Those who have taken health functional foods related to cognitive function improvement within 2 weeks of visit 1 8) A person whose daily dose of vitamin E preparation is 400 IU or more or who is expected to not be able to reduce the dose 9) Thyroid disease patients with TSH below 0.1 µIU/mL or above 10 µIU/mL 10) A person whose Creatinine is more than twice the upper limit of normal at the implementing institution 11) A person whose AST (GOT) or ALT (GPT) is more than 3 times the upper limit of normal 12) Patients with uncontrolled hypertension (systolic blood pressure of 160 mmHg or higher or diastolic blood pressure of 100 mmHg or higher, based on measurement after subject resting for 10 minutes) 13) Uncontrolled diabetes (fasting blood sugar of 180 mg/dL or more) 14) Pregnant or lactating women or those who plan to become pregnant during this human application test 15) Those who are sensitive or allergic to food ingredients for this human application test 16) Those who have participated in other interventional clinical trials (including human trials) within 3 months of the start of this human trial, or plan to participate in other interventional clinical trials (including human trials) after the start of this human trial 17) Those who are judged unsuitable by the tester for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADAS-cog 11 total score | — |
Secondary
| Measure | Time frame |
|---|---|
| ADAS-cog 11 memory domain score; ADAS-cog 11 language/performance score;Verbal Learning Test;Visual C.P.T;MoCA-K | — |
Countries
Korea, Republic of
Contacts
Public ContactJUNGHAN LEE
Wonkwang University. Iksan Korean Medicine Hospital
Outcome results
None listed